 The purpose of this trial are to evaluate the reduction of urinary albumin excretion by an angiotensin receptor blocker ARB, valsartan, in comparison with a calcium channel blocker CCB, amlodipine, in Japanese hypertensive patients with type 2 diabetes mellitus and microalbuminuria under strict blood pressure control, and to compare the additional effects of an ARB or a CCB in combination with angiotensin-converting enzyme ACE inhibitor treatment. 